Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019

12 November 2019 – St Andrews, Scotland – Pneumagen Ltd, focused on treating infectious disease and oncology by targeting the human glycome, today presented a poster at the RSVVW 2019 meeting in Accra, Ghana, hosted by the Respiratory Syncytial Virus Network (ReSViNET) Foundation.

The poster describes how sialic acids decorate the surfaces of most animal cells and are the receptor for the binding of many microbial pathogens, including the influenza virus. A host-targeted approach to the prevention or treatment of disease caused by sialic acid-targeting pathogens works by masking the receptor to prevent cell binding, entry and replication. Pneumagen has developed multivalent sialic acid-binding proteins which bind sialic acid with sub-nanomolar affinity, and which we have shown to protect mice from lethal doses of a range of influenza viruses, including H1N1, H7N9 and H5N1 (Connaris et al., 2014 PNAS 111, 6401-6406; Govorkova et al., 2015 AAC 59, 1495-1504).

Pneumagen recently investigated the potential of Neumifil as a preventative or treatment for respiratory syncytial virus (RSV) infection. The Company showed that Neumifil, when given prophylactically or as a treatment, leads to a significant reduction in lung virus titre in mice infected with hRSV-A2. The ability of Neumifil to reduce infection by two of the leading causes of respiratory disease, suggests its potential as a pan-viral biologic for the prevention and treatment of infection by a range of respiratory pathogens.

To view the full poster please click here to download.


About Pneumagen

Pneumagen is using its platform technology, GlycoTargeTM, to develop glycan targeted carbohydrate -binding module domains (mCBMs) derived from bacterial sialidases as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. These engineered mCBMs have been shown to prevent and treat respiratory infections by binding to epithelial cell surface sialic acid receptors present in the respiratory tract, used by several pathogens for entry.

Pneumagen’s lead product, NeumifilTM, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV) and Respiratory Syncytial Virus (RSV) infections. When administered intranasally in preclinical models, NeumifilTM has demonstrated prevention, treatment and post-exposure prophylaxis of IFV and RSV infection with no observed toxicity.


Contact details:

Katja Stout, Scius Communications


Douglas Thomson, Pneumagen